Kristoffer de Lara, MD
Interventional Pain Medicine · Germantown, MDNPI 1104109305
Payments from drug & device makers
Across 943 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- Abbott$3K
- Collegium Pharmaceutical, Inc.$2K
- Scilex Pharmaceuticals Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- AbbVie$1K
- plus $11K from 50 others
What the payments were for
- Travel & lodging$2,2169%
- Food & beverage$20,73787%
- Education$8544%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL PAIN MANAGEMENT$1,012
- PROCLAIM$815
- Proclaim IPG$780
- WAVEWRITER ALPHA$724
- mild Device Kit$565
- Stimrouter Implantable Kit$347
- Senza Spinal Cord Stimulation System$252
- Proclaim Family of SCS IPGs$241
- UBRELVY$240
- SYNCHROMEDII$191
- Evoke$180
- Omnia$133
- QULIPTA$125
- INFINITY$123
- LUCEMYRA$121
- JOURNAVX$116
- Evoke SCS$116
- INTELLIS ADAPTIVESTIM$111
- WaveWriter Alpha Prime 16$106
How this compares
$23,807 in reported general payments places this provider in the 80th percentile of 56 interventional pain medicine providers in Maryland.
See all interventional pain medicine providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 109 | $97,795 |
| MovantikNaloxegol Oxalate | 117 | $56,081 |
| Xtampza ErOxycodone Myristate | 104 | $54,117 |
| RelistorMethylnaltrexone Bromide | 18 | $46,385 |
| OxycontinOxycodone Hcl | 55 | $41,782 |
| Buprenorphine | 173 | $34,429 |
| ZtlidoLidocaine | 54 | $30,270 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 490 | $13,379 |
| Lidocaine | 75 | $8,622 |
| Gabapentin | 508 | $7,278 |
| Diclofenac Sodium | 77 | $6,996 |
| Pregabalin | 177 | $6,980 |
| Oxycodone Hcl | 371 | $6,295 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 187 | $5,013 |
| Fentanyl | 38 | $3,773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $2,395 | $151,912213 claims |
| Redhill Biopharma Inc.Movantik | $458 | $56,081117 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $1,410 | $46,38518 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $170 | $35,758220 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $1,479 | $30,27054 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 56 interventional pain medicine providers in Maryland.
Other interventional pain medicine in Germantown
- Mark ColemanPikesville$1.3M
- Marc LoevRockville$318K
- Anish PatelFrederick$311K
- Aneesh SinglaSalisbury$167K
- Charles SimmonsAnnapolis$73K
- Ali El-MohandesHagerstown$57K
- Michael WongBel Air$31K
- Anna IrwinBethesda$30K
- Dontese NicholsonBaltimore$27K
- Rajesh JariNottingham$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.